News for Gilead Sciences, Inc. (GILD)

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Air India Boeing jet crashes shortly after takeoff. Nvidia and Samsung to take minority stakes in robotics startup Skild AI - report. Chime Financial prices IPO at $27, above expected price.

**media[651594]**

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ETCompany ParticipantsDaniel P.

Key Takeaways: Gilead Sciences faces a temporary setback due to a clinical hold by the FDA on their experimental HIV drugs. Despite challenges, analysts

Gilead Sciences (GILD) has announced that its weekly oral HIV treatment study, involving the 1720/4182 combination, has been put on clinical hold. This decision

Gilead Sciences, Inc. (GILD) experienced a 2% decline in its stock price, reaching $111.14, following news that the U.S. Food and Drug Administration (FDA) has

As of midday Sunday, June 8, 2025, major U.S. stock indexes are holding steady following Friday's impressive gains that pushed the S&P 500 above the

Market Analysis by covering: S&P 500, Banco Santander, Gilead Sciences Inc. Read 's Market Analysis on Investing.com

Summary On May 30, 2025, Gilead Sciences Inc (GILD) announced the opening of the Bay Area Young Survivors Breast Cancer Memorial Garden in San Francisco's Golde

NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences:We recently commemorated the opening of the Bay Area Young Survivors Breast Cancer Memorial G

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. The following biotech companies are awaiting potential approvals in June 2025.

Gilead Sciences, Inc. (NASDAQ:GILD) Bernstein Annual Strategic Decisions Conference May 29, 2025 2:30 PM ETCompany ParticipantsDan O’Day - Chairman and...

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

**media[638992]**

**media[638490]**

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more about GILD stock here.

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC).

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC). Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant and meaningful improvement in progression-free survival compared to chemotherapy in first-line mTNBC patients who cannot receive immunotherapy. This marks the first substantial progress in over […]